证券之星消息，1月29日生物制品板块较上一交易日下跌1.3%，华兰疫苗领跌。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002880 | 卫光生物 | 30.07 | 4.59% | 8.81万 | | 2.66亿 | | 000661 | 长春高新 | 98.30 | 0.92% | 6.47万 | | 6.29亿 | | 300294 | 博雅生物 | 23.15 | 0.92% | 6.32万 | | 1.46亿 | | 300122 | 智飞生物 | 17.99 | 0.73% | - 43.69万 | | 7.78亿 | | 000403 | 派林生物 | 13.86 | 0.51% | 8.83万 | | 1.22亿 | | 600161 | 天坛生物 | 16.79 | 0.42% | 15.16万 | | 2.53亿 | | 6002 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Group 1 - The core point of the article is that Guangxi Yuchai Machinery Co., Ltd. has obtained a patent for a "Calibration Tool for Engine Torque Sensors," with the authorization announcement number CN115077788B, and the application date was July 2022 [1] - Guangxi Yuchai Machinery Co., Ltd. was established in 1993 and is located in Yulin City, primarily engaged in the manufacturing of specialized equipment [1] - The company has a registered capital of 4,729.89346 million RMB and has made investments in 17 enterprises, participated in 947 bidding projects, and holds 15 trademark registrations and 5,000 patent registrations [1] - Additionally, the company possesses 1,195 administrative licenses [1]

Group 1 - On January 4, a total of 7 companies were investigated by institutions, with 6 companies being surveyed by funds, highlighting a significant interest in certain firms [1] - Among the companies surveyed, Jingji Zhino (京基智农) attracted the most attention, with 23 funds participating in the investigation, followed by Tianyang Technology (天阳科技) with 21 funds and Yuxin Technology (宇信科技) with 14 funds [1] - The surveyed companies included 3 from the Shenzhen main board and 3 from the ChiNext board, indicating a diverse representation across different market segments [2] Group 2 - The total market capitalization of the surveyed A-share companies included 2 firms with a market value of less than 10 billion yuan, specifically Shanjiji Technology (熵基科技) and Jingji Zhino (京基智农) [3] - In terms of market performance, 5 out of the surveyed stocks increased in value over the past 5 days, with Jingji Zhino leading at a rise of 23.94%, followed by Shanjiji Technology at 13.77% and Jingbeifang (京北方) at 11.09% [3] - Notably, Jingbeifang experienced a net inflow of 216 million yuan in funds over the past 5 days, indicating strong investor interest, while Yuxin Technology and Jingji Zhino also saw significant net inflows of 103 million yuan and 67.98 million yuan, respectively [3]

（记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，派林生物发布公告称，2025年12月25日至2026年1月4日期间，派林生物接受易方达基金 等投资者调研，公司董事会秘书赵玉林参与接待，并回答了投资者提出的问题。 每经头条（nbdtoutiao）——AI泡沫破灭？美股下跌20%？量子计算颠覆加密货币？金价涨破1万美元？ 2026年华尔街和科技圈十大预测来了 ...

Group 1: Industry Outlook - The blood products industry is expected to experience significant growth due to factors such as economic development, aging population, and increased clinical demand for blood products [1] - In 2023 and 2024, the industry is projected to see a supply-demand mismatch, with a 5% increase in plasma collection expected in the first half of 2025 [2] Group 2: Company Performance and Projections - The company anticipates a cash dividend of approximately CNY 256 million for 2024, representing 41.79% of the net profit attributable to shareholders for 2023 [5] - For 2025, the expected cash dividend remains at CNY 256 million, accounting for 34.33% of the net profit for 2024 [6] - In the first three quarters of 2025, the company's revenue and net profit attributable to shareholders decreased due to capacity expansion efforts [7] Group 3: Production and Capacity - The company expects to collect nearly 1,600 tons of plasma in 2025, with a projected output of over 1,400 tons [8] - The total production capacity has been expanded to over 3,000 tons following the completion of capacity upgrades in 2025 [7] Group 4: Research and Development - The company is advancing the development of the fourth generation of immunoglobulin, with expected regulatory approval for new indications by 2027 [9][10] - The company is also focusing on the development of human coagulation factors, with anticipated approvals for new products in 2027 [10] Group 5: Market Expansion and Control Transfer - The company is actively pursuing overseas market opportunities, with plans for regulatory registration and export sales [3] - The transfer of control to China National Biological is in progress, with significant steps taken towards finalizing the transaction by June 30, 2026 [4][12] Group 6: Infrastructure and Product Range - The company operates a total of 38 plasma collection stations, ranking third in the industry [11] - The product range includes 11 varieties across multiple specifications, also placing the company third in the industry [11]

天眼查资料显示，广西玉柴机器股份有限公司，成立于1993年，位于玉林市，是一家以从事专用设备制 造业为主的企业。企业注册资本47298.9346万人民币。通过天眼查大数据分析，广西玉柴机器股份有限 公司共对外投资了17家企业，参与招投标项目945次，财产线索方面有商标信息15条，专利信息5000 条，此外企业还拥有行政许可1195个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 国家知识产权局信息显示，广西玉柴机器股份有限公司取得一项名为"一种发动机机油冷却器布置系 统"的专利，授权公告号CN117552853B，申请日期为2023年12月。 作者：情报员 ...

国家知识产权局信息显示，广西玉柴机器股份有限公司取得一项名为"一种发动机机油压力建立时间测 试系统、方法及传感器"的专利，授权公告号CN114486268B，申请日期为2022年3月。 天眼查资料显示，广西玉柴机器股份有限公司，成立于1993年，位于玉林市，是一家以从事专用设备制 造业为主的企业。企业注册资本47298.9346万人民币。通过天眼查大数据分析，广西玉柴机器股份有限 公司共对外投资了17家企业，参与招投标项目945次，财产线索方面有商标信息15条，专利信息5000 条，此外企业还拥有行政许可1195个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：情报员 ...

近日，派林生物发布公告称，此前公司已披露相关收购协议及控制权拟变更的提示性公告，中国生物技 术股份有限公司与公司控股股东共青城胜帮英豪投资合伙企业（有限合伙）签署了《收购框架协议》， 胜帮英豪拟将所持公司21.03%股份转让给中国生物。近期双方签署了《股份转让协议之补充协议》。 若本次权益变动实施并完成，公司的控股股东及实际控制人将发生变更。中国生物将成为公司的控股股 东，中国医药集团有限公司将成为公司的实际控制人。 （派林生物公告） ...

关键词： 财经频道 财经资讯 (资料图片仅供参考) 证券日报网讯12月28日，派林生物（000403）发布公告称，控股股东胜帮英豪与中国生物签署《股份转 让协议之补充协议》，因本次交易已进入国资及反垄断审查程序，胜帮英豪将所持公司21.03%股份转 让给中国生物最终截止日延长至2026年6月30日。交易完成后中国医药集团将成为公司实控人。 ...